The longitudinal study of relationship between changes in cognitive function and beta amyloid accumulation in the brain using 11C-Pib PET

The longitudinal study of relationship between changes in cognitive function and beta amyloid accumulation in the brain using 11C-Pib PET - The study investigating cognitive decline and beta amyloid accumulation in the brain

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030430

Enrollment

100

Registered

2017-12-18

Start date

2017-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer disease, mild cognitive decline, preclinical Alzheimer disease

Interventions

The radioactive agent of 11C-PiB (555MBq)is administered. PET scan is performed once a year for three years. The radioactive agent of FDG (185MBq) is administered. PET scan is performed once a year fo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Mild and moderate grade of Alzheimer disease (MMSE 18 - 23), mild cognitive decline patients (MMSE 24 - 26) are recruited. Normal cognitive subjects also participate in this study. They are classified into two groups; preclinical Alzheimer disease group (amyloid positive) and amyloid negative group at the initial 11C-PiB PET study.

Exclusion criteria

Exclusion criteria: Depression patients

Design outcomes

Primary

Measure	Time frame
11C-PiB PET, FDG-PET and cognitive tests are performed every year and followed for three years. PiB PET shows accumulation of beta amyloid protein, and FDG PET reveals glucose metabolisms in the brain. As cognitive batteries, MMSE, FAB, MoCA-J and WMSR are performed.	—

Countries

Japan

Contacts

Public ContactTakenobu Murakami

Fukushima Medical University Neurology

takebou@fmu.ac.jp024-547-1248

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026